European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention
Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated in cSCC etiopathogenesis include ultraviolet radiation exposure and chronic photoaging, age, male sex, immunosuppression, smoking and genetic factors. A collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation of Research and Treatment of Cancer (EORTC) was formed to update recommendations on cSCC classification, diagnosis, risk stratific...
Source: European Journal of Cancer - February 26, 2020 Category: Cancer & Oncology Authors: Alexander J. Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Veronique Bataille, Lars Bastholt, Brigitte Dreno, Maria Concetta Fargnoli, Ana Maria Forsea, Cecille Frenard, Catherine Α. Harwood, Axel Hauschild, Christoph Hoeller, Lidija Kandolf-Se Tags: Guidelines Source Type: research

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
In order to update recommendations on treatment, supportive care, education  and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer was formed. Recommendations w ere based on evidence-based literature review, guidelines and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable) a...
Source: European Journal of Cancer - February 26, 2020 Category: Cancer & Oncology Authors: Alexander J. Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Veronique Bataille, Lars Bastholt, Brigitte Dreno, Maria Concetta Fargnoli, Ana M. Forsea, Cecille Frenard, Catherine A. Harwood, Axel Hauschild, Christoph Hoeller, Lidija Kandolf-Sekulo Tags: Guidelines Source Type: research

Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?
Monoclonal antibodies in oncology, used as targeted molecular therapy, linked to cytotoxic compound or directed against immune checkpoints, feature complex PKs essentially determined by their physicochemical characteristics. The increasing number of studies shows the existence of Pharmacokinetics/Pharmacodynamic (PK/PD) relationships for many of them. Although more studies, especially conducted in early clinical phases, are needed, existing studies highlight the need to integrate PK data for monoclonal antibodies in all phases of their development and the therapeutic management of patients with cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 20, 2020 Category: Cancer & Oncology Authors: Olivier Mir, Sophie Broutin, Aude Desnoyer, Julia Delahousse, Nathalie Chaput, Angelo Paci Tags: Review Source Type: research

Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies
Immune checkpoint inhibitors are monoclonal antibodies (mAbs) directed against negative immunologic regulators that are used to restore the immune response against cancer. Approved drugs include anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death-ligand 1 (PD-L1) antibodies exhibiting pharmacokinetic (PK) characteristics typical of mAbs. Most factors such as age, sex, ethnicity, tumour burden, performance status and immunogenicity, but not body weight, do not seem to affect drug clearance clinically. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Aude Desnoyer, Sophie Broutin, Julia Delahousse, Christophe Maritaz, Louis Blondel, Olivier Mir, Nathalie Chaput, Angelo Paci Tags: Review Source Type: research

Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates  and bispecific T-cell engagers
More than 25 therapeutic monoclonal antibodies (mAbs) used in oncology have been approved since 1997. Their nature has been largely modified through the last 20 years, from the chimeric IgG1 rituximab with pharmacokinetic parameters specific of murin or chimeric mAbs to humanized or human mAbs. Doses and administration frequency have been chosen based on this nature. More recently, the developed and registered mAbs are mostly IgG1, IgG2, IgG3 or IgG4 humanized or 100% human. Therefore, their behavior is different from the first mAbs authorized leading to lower systemic clearance and shorter half-life due to higher cellular...
Source: European Journal of Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Angelo Paci, Aude Desnoyer, Julia Delahousse, Louis Blondel, Christophe Maritaz, Nathalie Chaput, Olivier Mir, Sophie Broutin Tags: Review Source Type: research

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
We report outcomes from this trial. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 3, 2020 Category: Cancer & Oncology Authors: Enriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, Manuel Cobo, Konstantin Laktionov, Maria Szilasi, Raffaele Califano, Enric Carcereny, Richard Griffiths, Luis Paz-Ares, Renata Duchnowska, Miriam Alonso Garcia, Dolores Isla, Jacek Jassem, Wiebke Appel, J Tags: Original Research Source Type: research

Reviewers 2019
The Editors of the European journal of Cancer would like to take this opportunity to express their gratitude to all the individuals who acted as reviewers in the year 2019. Particular thanks are due to: (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 1, 2020 Category: Cancer & Oncology Source Type: research

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
The RAINBOW trial showed that second-line ramucirumab with paclitaxel prolongs overall survival (OS) and progression-free survival (PFS) compared with placebo plus paclitaxel for treatment of advanced gastric/gastroesophageal junction cancer. Plasma samples were collected from patients during the trial and tested to identify predictive and prognostic biomarkers. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 31, 2020 Category: Cancer & Oncology Authors: E. Van Cutsem, K. Muro, D. Cunningham, G. Bodoky, A. Sobrero, S. Cascinu, J. Ajani, S.C. Oh, S.E. Al-Batran, Z.A. Wainberg, S.R. Wijayawardana, S. Melemed, D. Ferry, R.R. Hozak, A. Ohtsu, the RAINBOW Investigators Tags: Original Research Source Type: research

Is it time to redefine cisplatin ineligibility in metastatic urothelial cancer?
Cisplatin-based combination chemotherapy remains the standard of care in first-line metastatic urothelial carcinoma (mUC) with response rates of approximately 50% and a median overall survival of 13 –15 months [1]. However, due to renal dysfunction, poor performance status and comorbidities, many patients will be considered cisplatin-ineligible and be offered regimens such as gemcitabine and carboplatin (GCa). Although better tolerated, GCa is inferior to cisplatin-based regimens, underscorin g the need for novel therapeutic strategies in the cisplatin-ineligible setting [2]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 31, 2020 Category: Cancer & Oncology Authors: Srikala S. Sridhar Tags: Editorial Source Type: research

Induction of apoptosis increases sensitivity to detect cancer mutations in plasma
The study of cell-free DNA (cfDNA), namely the fraction derived from tumors (ctDNA), is a clinically relevant noninvasive biomarker for cancer management. However, the intrinsic low abundance of ctDNA in plasma limits its implementation in the clinic. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 31, 2020 Category: Cancer & Oncology Authors: Joana F. Marques, Susana Junqueira-Neto, Jorge Pinheiro, Jos é C. Machado, José L. Costa Tags: Original Research Source Type: research

The role of site-specific therapy for cancers of unknown of primary: A meta-analysis
Cancers of unknown primary (CUP) are among the most common causes of death due to cancer, are associated with a poor prognosis and have few therapeutic options available. Molecularly-guided site-specific treatments were explored based on the assumption that CUP are similar in their response to treatment  of predicted primary tumours. Given the discordant results between these studies, a meta-analysis using a random-effects model and the inverse variance method was performed. MEDLINE and conference abstracts of American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology ( ESMO) meetings w...
Source: European Journal of Cancer - January 30, 2020 Category: Cancer & Oncology Authors: Elie Rassy, Ziad Bakouny, Toni K. Choueiri, Eliezer M. Van Allen, Karim Fizazi, F. Anthony Greco, Nicholas Pavlidis Tags: Current Perspective Source Type: research

Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)
We report the clinical findings and results of treatment in the cohort of patients with inflammatory myofibroblastic tumor (IMT) managed according to the European pediatric Soft Tissue Sarcoma Study Group (EpSSG) protocol from 2005 to 2016. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 30, 2020 Category: Cancer & Oncology Authors: Michela Casanova, Bernadette Brennan, Rita Alaggio, Anna Kelsey, Daniel Orbach, Max M. van Noesel, Nadege Corradini, Veronique Minard-Colin, Ilaria Zanetti, Gianni Bisogno, Soledad Gallego, Johannes H.M. Merks, Gian Luca De Salvo, Andrea Ferrari Tags: Original Research Source Type: research

Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)
Up to 50% of men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, vincristine and cisplatin/BEP), met response targets in a randomised, phase II trial (74% complete response or partial response marker negative, 90% confidence interval (CI) 61% –85%). (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 30, 2020 Category: Cancer & Oncology Authors: Fay H. Cafferty, Jeff D. White, Jonathan Shamash, Ivo Hennig, Sally P. Stenning, Robert A. Huddart, TE23 Trial Management Group and Collaborators Tags: Original Research Source Type: research

Reply to the letter to the editor: ‘Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images’
At the end of the recruitment period, 14 addresses had acknowledged the invitation by e-mail, and these physicians were counted as invited to the survey. As described in the manuscript, participants with and without board certification were eligible because pathologists with and without board certification assess histologic slides in clinical routine. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 30, 2020 Category: Cancer & Oncology Authors: Achim Hekler, Jochen S. Utikal, Wiebke Solass, Max Schmitt, Joachim Klode, Dirk Schadendorf, Wiebke Sondermann, Cindy Franklin, Felix Bestvater, Dieter Krahl, Christof von Kalle, Stefan Fr öhling, Titus J. Brinker Tags: Letter to the Editor Source Type: research

Should a neck dissection be performed on patients with cN0 adenoid cystic carcinoma? A REFCOR propensity score matching study
The objective of this study is to analyse the influence of ND on event-free survival (EFS) for patients with cN0 ACC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 30, 2020 Category: Cancer & Oncology Authors: Sarah Atallah, Antoine Moya-Plana, Olivier Malard, Gilles Poissonnet, Nicolas Fakhry, J érémie Bettoni, Patrice Gallet, Pierre Ransy, Sebastien Vergez, Ludovic De Gabory, Diane Evrard, Maria Lesnik, Pierre Philouze, Chloé Bertolus, Philippe Schultz, Sy Tags: Original Research Source Type: research

The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients
We present herein an evidence-based, joint global consensus guideline approach to the management of this disease focussing on: molecular genetics, indications for an active treatment, and available systemic therapeutic options. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 28, 2020 Category: Cancer & Oncology Authors: The Desmoid Tumor Working Group Tags: Review Source Type: research

Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Few patients with cSCC experience metastases, but the prognosis of advanced cSCC (acSCC) is dismal. Evidence regarding systemic therapy for acSCC is limited. Therefore, we aimed to determine the most effective systemic treatment for acSCC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 28, 2020 Category: Cancer & Oncology Authors: Dai Ogata, Kenjiro Namikawa, Masaki Otsuka, Jun Asai, Hisoshi Kato, Masahito Yasuda, Takeo Maekawa, Taku Fujimura, Junji Kato, Tatsuya Takenouchi, Kotaro Nagase, Masakazu Kawaguchi, Tatsuya Kaji, Yutaka Kuwatsuka, Yoshitsugu Shibayama, Toshihiro Takai, Ma Tags: Original Research Source Type: research

Indications for hyperthermic intraperitoneal chemotherapy  with cytoreductive surgery: a systematic review
The purpose of the present review was to describe evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC), with cytoreductive surgery (CRS), in patients with a diagnosis of mesothelioma, appendiceal (including appendiceal mucinous neoplasm), colorectal, gastric, ovarian or primary peritoneal carcinoma. Relevant studies were identified from a systematic MEDLINE and EMBASE search of studies published from 1985 to 2019. Studies were included if they were RCTs. If no RCTs were identified, prospective and retrospecctive comparative studies (where confounders are controlled for studies with greater than ...
Source: European Journal of Cancer - January 24, 2020 Category: Cancer & Oncology Authors: Rebecca C. Auer, Duvaraga Sivajohanathan, Jim Biagi, James Conner, Erin Kennedy, Taymaa May Tags: Review Source Type: research

A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer
The unmet need for predictive biomarkers emerged from the unpredictable pattern of response to androgen signalling inhibition in metastatic castration-resistant prostate cancer (mCRPC). Here, we report on the testing of a previously identified candidate androgen signalling signature associated with response to androgen signalling inhibition. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 24, 2020 Category: Cancer & Oncology Authors: Myrto Boukovala, Nicholas Spetsieris, Justin A. Weldon, Alexandros Tsikkinis, Anh Hoang, Ana Aparicio, Shi-Ming Tu, John C. Araujo, Amado J. Zurita, Paul G. Corn, Lance Pagliaro, Jeri Kim, Jennifer Wang, Sumit K. Subudhi, Nizar M. Tannir, Christopher J. L Tags: Original Research Source Type: research

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients
The third multistakeholder Paediatric Strategy Forum  organised by ACCELERATE and the European Medicines Agency focused on immune checkpoint inhibitors for use in combination therapy in children and adolescents. As immune checkpoint inhibitors, both as monotherapy and in combinations have shown impressive success in some adult malignancies and early phase trials in children of single agent checkpoint inhibitors have now been completed, it seemed an appropriate time to consider opportunities for paediatric studies of checkpoint inhibitors used in combination. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 24, 2020 Category: Cancer & Oncology Authors: Andrew D.J. Pearson, Claudia Rossig, Giovanni Lesa, Scott J. Diede, Susan Weiner, John Anderson, Juliet Gray, Birgit Geoerger, Veronique Minard-Colin, Lynley V. Marshall, Malcolm Smith, Paul Sondel, Marcis Bajars, Claudia Baldazzi, Elly Barry, Sam Blackma Tags: Original Research Source Type: research

Support of a molecular tumour board by an evidence-based decision management system for precision oncology
Reliable and reproducible interpretation of molecular aberrations constitutes a bottleneck of precision medicine. Evidence-based decision management systems may improve rational therapy recommendations. To cope with an increasing amount of complex molecular data in the clinical care of patients with cancer, we established a workflow for the interpretation of molecular analyses. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 23, 2020 Category: Cancer & Oncology Authors: Mario Lamping, Manuela Benary, Serge Leyvraz, Clemens Messerschmidt, Eric Blanc, Thomas Kessler, Moritz Sch ütte, Dido Lenze, Korinna Jöhrens, Susen Burock, Konrad Klinghammer, Sebastian Ochsenreither, Christine Sers, Reinhold Schäfer, Ingeborg Tinhofe Tags: Original Research Source Type: research

Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer
The objective of this study was to derive a protein biomarker signature for early detection of CRC and its precursor advanced adenoma (AA). In a two-stage design, 270 protein markers were measured by liquid chromatography/multiple reaction monitoring/mass spectrometry  in plasma samples of discovery and validation sets. In the discovery set consisting of 100 newly diagnosed CRC cases and 100 age- and sex-matched controls free of neoplasm at screening colonoscopy, the algorithms predicting the presence of early- or late-stage CRC were derived by Lasso regression and .632 + bootstrap. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 21, 2020 Category: Cancer & Oncology Authors: Megha Bhardwaj, Korbinian Weigl, Kaja Tikk, Tim Holland-Letz, Petra Schrotz-King, Christoph H. Borchers, Hermann Brenner Tags: Original Research Source Type: research

Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review
Organised cervical cancer (CC) screening programmes are delivered in many different ways across the European Union and its regions. Our aim was to systematically review the impact of these programs on CC mortality. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 21, 2020 Category: Cancer & Oncology Authors: Erik E.L. Jansen, Nadine Zielonke, Andrea Gini, Ahti Anttila, Nereo Segnan, Zolt án Vokó, Urška Ivanuš, Martin McKee, Harry J. de Koning, Inge M.C.M. de Kok, EU-TOPIA consortium Tags: Review Source Type: research

Melanoma recognition by a deep learning convolutional neural network —Performance in different melanoma subtypes and localisations
Deep learning convolutional neural networks (CNNs) show great potential for melanoma diagnosis. Melanoma thickness at diagnosis among  others depends on melanoma localisation and subtype (e.g. advanced thickness in acrolentiginous or nodular melanomas). The question whether CNN may counterbalance physicians’ diagnostic difficulties in these melanomas has not been addressed. We aimed to investigate the diagnostic performance of a CNN with approval for the European market across different melanoma localisations and subtypes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 20, 2020 Category: Cancer & Oncology Authors: Julia K. Winkler, Katharina Sies, Christine Fink, Ferdinand Toberer, Alexander Enk, Teresa Deinlein, Rainer Hofmann-Wellenhof, Luc Thomas, Aimilios Lallas, Andreas Blum, Wilhelm Stolz, Mohamed S. Abassi, Tobias Fuchs, Albert Rosenberger, Holger A. Haenssl Tags: Original Research Source Type: research

Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours
Tumour-infiltrating lymphocytes (TILs) are an emerging biomarker in breast cancer (BC) [1]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 20, 2020 Category: Cancer & Oncology Authors: Carmen Criscitiello, Giuseppe Curigliano Tags: Editorial Source Type: research

Intratumoural immunotherapies in oncology
Although immune checkpoint inhibitors have become the standard of care for many tumours, the majority of patients fail to achieve sustained benefit, often owing to the lack of a T-cell inflamed tumour microenvironment (TME). Directly injected intratumoural therapies present a potential strategy to induce T-cell inflammation and convert a ‘cold’ immune-inert TME into a ‘hot’ immune-inflamed TME. Various approaches including chemoablation, oncolytic viral therapy, cytokines and agents targeting innate immunity such as Toll-like receptor agonists and stimulator of interferon genes agonists are in ...
Source: European Journal of Cancer - January 18, 2020 Category: Cancer & Oncology Authors: Wen Xu, Victoria G. Atkinson, Alexander M. Menzies Tags: Current Perspective Source Type: research

Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial
To investigate long-term results of patients with hormonal receptor –positive breast cancer treated with breast-conserving surgery (BCS) and consecutive endocrine therapy (ET) with or without whole breast irradiation (WBI). (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 18, 2020 Category: Cancer & Oncology Authors: Gerd Fastner, Felix Sedlmayer, Joachim Widder, Martina Metz, Hans Geinitz, Karin Kapp, Christian Fesl, Lidija S ölkner, Richard Greil, Raimund Jakesz, Werner Kwasny, Dietmar Heck, Vesna Bjelic-Radisic, Marija Balic, Herbert Stöger, Ursula Wieder, Ronald Tags: Clinical Trial Source Type: research

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy
The prognostic value of tumour-infiltrating lymphocytes (TILs) differs by breast cancer (BC) subtype. The aim of this study was to evaluate TILs in stage III BC in the context of BRCA1/2-like phenotypes and association with outcome and benefit of intensified platinum-based chemotherapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 16, 2020 Category: Cancer & Oncology Authors: Leonora de Boo, Ashley Cimino-Mathews, Yoni Lubeck, Antonios Daletzakis, Mark Opdam, Joyce Sanders, Erik Hooijberg, Annelot van Rossum, Zuzana Loncova, Dietmar Rieder, Zlatko Trajanoski, Marieke Vollebergh, Marcelo Sobral-Leite, Koen van de Vijver, Annegi Tags: Original Research Source Type: research

Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer
Fulvestrant is a selective oestrogen receptor downregulator, with a distinct mode of action  [1]. Fulvestrant is an effective treatment option in postmenopausal women with advanced hormone receptor–positive breast cancer [2,3]. After the recent publications of pivotal randomised trial results assessing fulvestrant in combination with CDK (Cyclin-dependent kinase) 4/6 inhibitors or alpel isib, fulvestrant is likely to be increasingly used in women with advanced oestrogen receptor-positive breast cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: E. Samuel, C. Chiang, R. Jennens, D. Faulkner, P.A. Francis Tags: Letter to the Editor Source Type: research

JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer
Overexpression of c-Myc is commonly seen in human ovarian cancers, and this could be a potentially novel therapeutic target for this disease. JQ1, a selective small-molecule BET (Bromodomain and extraterminal domain family) bromodomain (BRDs) inhibitor, has been found to suppress tumour progression in several cancer cell types. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Tina Bagratuni, Nefeli Mavrianou, Nikolaos G. Gavalas, Kimon Tzannis, Calliope Arapinis, Michael Liontos, Maria I. Christodoulou, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Efstathios Kastritis, Andreas Scorilas, Meletios A. Dimopoulo Tags: Original Research Source Type: research

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib
Metastatic soft tissue sarcomas (STSs) management remains an unmet medical need. We assessed the activity and safety of regorafenib in patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, Antoine Italiano, Sebastien Salas, Corinne Delcambre, Emmanuelle Bompas, Fran çois Bertucci, Esma Saada-Bouzid, Loïc Chaigneau, Christine Chevreau, Thomas Brodowicz, Emili Tags: Original Research Source Type: research

Cervical cancer mortality in young adult European women
The process of social, political and economic transformation, which took place in Central and Eastern Europe in the early 90's, has affected many spheres of Europeans' lives, including health-associated issues. These changes also had an impact on mortality rates due to cervical cancer (CC). Therefore, the aim of this study was to analyse CC mortality trends in Europe after 1990. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Cezary Wojtyla, Kinga Janik-Koncewicz, Carlo La Vecchia Tags: Original Research Source Type: research

The CXCR2/CXCL2 signalling pathway – An alternative therapeutic approach in high-grade glioma
Besides VEGF, alternative signalling via CXCR2 and its ligands CXCL2/CXCL8 is a crucial part of angiogenesis in glioblastoma. Our aim was to understand the role of CXCR2 for glioma biology and elucidate the therapeutic potential of its specific inhibition. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: G üliz Acker, Julia Zollfrank, Claudius Jelgersma, Melina Nieminen-Kelhä, Irina Kremenetskaia, Susanne Mueller, Adnan Ghori, Peter Vajkoczy, Susan Brandenburg Tags: Original Research Source Type: research

Positron-emission tomography –based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma
Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Connie L. Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying, John F. Gerecitano, Paul A. Hamlin, Steve M. Horwitz, Erel Joffe, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Ariela Noy, Colette Owens, Lia M. P Tags: Original Research Source Type: research

Pan-cancer immunogenomic analyses reveal sex disparity in the efficacy of cancer immunotherapy
Immune checkpoint inhibitors (ICIs), such as blockers of programmed cell death 1 (PD-1), programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen-4  are promising cancer therapeutics which have already been used in a variety of cancers and exhibit huge benefits [1]. However, sex-based dimorphism on the efficacy of ICIs was recently revealed in various cancers. It was suggested that male cancer patients benefit more from ICIs than the female co unterparts [2], while the underlying mechanism still remains to be elucidated. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Peng-Fei Wang, Hai-Feng Song, Qian Zhang, Chang-Xiang Yan Tags: Letter to the Editor Source Type: research

Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases
Pembrolizumab, a monoclonal antibody that binds to and inhibits the programmed cell death protein 1  receptor, belongs to the immune checkpoint inhibitor (ICI) class of cancer therapeutics. It is an effective second-line treatment for metastatic or advanced urothelial cancer [1]. However, ICIs including pembrolizumab are often associated with immune-related adverse events (irAEs), including pneum onitis, pancreatitis, dermatitis, myositis and nephritis. There are, however, few reports of nail toxicities following ICI treatment. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Yuriko Sugihara, Taketo Kawai, Daisuke Yamada, Chiaki Furuyama, Yusuke Sato, Haruki Kume Tags: Letter to the Editor Source Type: research

Hyperprogression upon immunotherapy: A chance for (hyper-)progress
Although immunotherapy has revolutionised the treatment of cancer, accumulating evidence suggests that immune checkpoint inhibition might be detrimental in a subset of patients who experience paradoxical acceleration of their disease upon immunotherapy [1]. These patients, the so-called ‘hyperprogressors’, account for 6–29% of all patients treated with anti-PD(L)1 antibodies [2]. Although hypotheses have been suggested to explain this phenomenon (including boosting of regulatory T cells, increased T-cell exhaustion because of upregulation of alternative checkpoints, polarisat ion of immunosuppressive subs...
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Roch Houot, Aur élien Marabelle, Stéphane Champiat Tags: Letter to the Editor Source Type: research

Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma
Uveal melanoma (UM) is a rare and malignant intraocular tumour with a dismal prognosis. Despite a good control of the primary tumour by radiation or surgery, up to 50% of patients subsequently develop metastasis for which no efficient treatment is yet available. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Didier Decaudin, Estelle Frisch Dit Leitz, Fariba Nemati, Malcy Tarin, Adnan Naguez, Mohamed Zerara, Benjamin Marande, Raquel Vivet-Noguer, Ensar Halilovic, Claire Fabre, Aart Jochemsen, Sergio Roman-Roman, Samar Alsafadi Tags: Original Research Source Type: research

Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer
Both peripherally inserted central catheters (PICCs) and implanted port catheters (PORTs) are used for adjuvant chemotherapy (ACT) administration in patients with early breast cancer (EBC). We aimed to compare the safety between PICCs and PORTs in this setting. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Florian Clatot, Maxime Fontanilles, Laureline Lefebvre, Justine Lequesne, Corinne Veyret, Cristina Alexandru, Marianne Leheurteur, C écile Guillemet, Sophie Gouérant, Camille Petrau, Jean-Christophe Théry, Olivier Rigal, Cristian Moldovan, Isabelle Ten Tags: Original Research Source Type: research

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
T-DM1 has been approved for the treatment of HER2+ breast cancer. Cardiac dysfunction is a side effect of trastuzumab, a component of T-DM1. However, little is known about T-DM1-associated cardiotoxicity. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Noam Pond é, Lieveke Ameye, Matteo Lambertini, Marianne Paesmans, Martine Piccart, Evandro de Azambuja Tags: Original Research Source Type: research

Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome
Immune checkpoint inhibitors (ICIs) are associated with a unique spectrum of immune-related adverse events (irAEs) that are different from those occurring after conventional chemotherapy. Despite the risk of irAE recurrence, re-administration of ICIs after high-grade irAEs is critical, when considering their potential clinical benefits. Here, we report the first known case wherein pembrolizumab, an anti –programmed death 1 (PD-1) monoclonal antibody, was successfully re-administered with corticosteroids in a patient with severe nephrotic syndrome (NS) that developed during pembrolizumab therapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Susumu Saito, Tsukasa Kadota, Mina Gochi, Masamichi Takagi, Kazuyoshi Kuwano Tags: Letter to the Editor Source Type: research

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Claus Garbe, Teresa Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, Lars Bastholt, Veronique Bataille, Veronique del Marmol, Brigitte Dr éno, Maria Concetta Fargnoli, Jean-Jacques Grob, Christoph Höller, Roland Kaufmann, Aimilios Lallas, Celeste L Tags: Guidelines Source Type: research

Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines”
The European interdisciplinary guidelines on the diagnosis and treatment of basal cell carcinoma (BCC) are a thorough updated and expanded review of the literature [1]. The guidelines provide guidance for physicians to optimise BCC care. We strongly agree with emphasising personalised care and an individualised approach for each patient and tumour. In addition, we would like to comment on the extensive safety margins advised for conventional (2D) surgical excision of high-risk BCCs and the proposed frequent follow-up of patients with a history of BCC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Lieke C.J. van Delft, Eva van Loo, Klara Mosterd, Nicole W.J. Kelleners-Smeets Tags: Editorial Comment Source Type: research

Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review
The aim of this study was to quantify the impact of organised mammography screening on breast cancer mortality across European regions. Therefore, a systematic review was performed including different types of studies from all European regions and stringently used clearly defined quality appraisal to summarise the best evidence. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Nadine Zielonke, Andrea Gini, Erik E.L. Jansen, Ahti Anttila, Nereo Segnan, Antonio Ponti, Piret Veerus, Harry J. de Koning, Nicolien T. van Ravesteyn, Eveline A.M. Heijnsdijk, EU-TOPIA consortium Tags: Review Source Type: research

Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review
Populations differ with respect to their cancer risk and screening preferences, which may influence the performance of colorectal cancer (CRC) screening programs. This review aims to systematically compare the mortality effect of CRC screening across European regions. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Andrea Gini, Erik E.L. Jansen, Nadine Zielonke, Reinier G.S. Meester, Carlo Senore, Ahti Anttila, Nereo Segnan, Dominika Novak Mlakar, Harry J. de Koning, Iris Lansdorp-Vogelaar, EU-TOPIA consortium Tags: Review Source Type: research

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600 –mutant melanoma
BRAF/MEK inhibitor combinations are established treatments for BRAF V600 –mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS). Here, we report an updated analysis of the COLUMBUS (COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in BRAF mutant Unresectable Skin cancer) trial with long-term follow-up . (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 2, 2020 Category: Cancer & Oncology Authors: Paolo A. Ascierto, Reinhard Dummer, Helen J. Gogas, Keith T. Flaherty, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Jan Willem B. de Groot, Carmen Loquai, Ashwin Gollerkeri, Michael D. Pickard, Tags: Original Research Source Type: research

A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas
Chemotherapy objective response rates (ORRs) in metastatic soft tissue sarcoma (STS) are typically 20 –40% with median progression-free survival (PFS) less than 6 months. Lurbinectedin is a new anticancer agent under investigation. The primary objective of this three-arm, phase II study was to determine the disease control rate (DCR = ORR + stable disease [SD]) at 24 weeks of lurbinectedin a lone or with chemotherapy in STS. Eligible patients included adults with ≤2 prior cytotoxic therapies. Study cohorts were: stratum A (StrA; anthracycline-naive), lurbinectedin/doxorubicin; stratum...
Source: European Journal of Cancer - December 31, 2019 Category: Cancer & Oncology Authors: Gregory M. Cote, Edwin Choy, Tianqi Chen, Adrian Marino-Enriquez, Jeffrey Morgan, Priscilla Merriam, Katherine Thornton, Andrew J. Wagner, Michael J. Nathenson, George Demetri, Suzanne George Tags: Original Research Source Type: research

Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition
Adding cyclin-dependent kinase (CDK) inhibitor to endocrine treatment improves outcome in œstrogen receptor (ER) positive metastatic breast cancer, but identifying the subset of patients who benefit is challenging. Response is potentially associated with ER expression heterogeneity. This is because, unlike the primary tumour in the breast that is localized to the organ, the metastatic b reast cancer has spread and continues to spread to distant locations in the body such as bones, lungs, liver, axial skeleton, even to the central nervous system like the brain, wherefrom obtaining biopsies are not easy, and also, the ...
Source: European Journal of Cancer - December 28, 2019 Category: Cancer & Oncology Authors: Jorianne Boers, Clasina M. Venema, Erik F.J. de Vries, Andor W.J.M. Glaudemans, Thomas C. Kwee, Ed Schuuring, John W.M. Martens, Sjoerd G. Elias, Geke A.P. Hospers, Carolina P. Schr öder Tags: Original Research Source Type: research

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Cabozantinib improved progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy in the phase III METEOR trial (NCT01865747). Limited data are available on the use of targeted therapies in older patients with advanced RCC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 27, 2019 Category: Cancer & Oncology Authors: Frede Donskov, Robert J. Motzer, Eric Voog, Elizabeth Hovey, Carsten Gr üllich, Louise M. Nott, Katharine Cuff, Thierry Gil, Niels Viggo Jensen, Christine Chevreau, Sylvie Negrier, Reinhard Depenbusch, Lothar Bergmann, Izzy Cornelio, Anne Champsaur, Bern Tags: Original Research Source Type: research

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Previous analyses of BREAK-2 and BREAK-3 showed that durable outcomes lasting ≥3 years are achievable with dabrafenib in some patients with BRAF V600-mutant metastatic melanoma (MM); however, additional follow-up is needed to fully characterise the long-term impact of dabrafenib in these patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 19, 2019 Category: Cancer & Oncology Authors: Axel Hauschild, Paolo A. Ascierto, Dirk Schadendorf, Jean Jacques Grob, Antoni Ribas, Felix Kiecker, Caroline Dutriaux, Lev V. Demidov, C éleste Lebbé, Piotr Rutkowski, Christian U. Blank, Ralf Gutzmer, Michael Millward, Richard Kefford, Tomas Haas, Ant Tags: Original Research Source Type: research